Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17280502rdf:typepubmed:Citationlld:pubmed
pubmed-article:17280502lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:17280502lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:17280502lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:17280502pubmed:issue1lld:pubmed
pubmed-article:17280502pubmed:dateCreated2007-2-6lld:pubmed
pubmed-article:17280502pubmed:abstractTextAnalysis of the patterns of gene expression in breast cancer suggests that it is not a single entity, but is comprised of several biologically distinct subtypes with characteristic molecular profiles. These molecular profiles confirm the clinical impression that estrogen receptor (ER)-negative differs from ER-positive, and expands our understanding by identifying breast cancer subtypes, including the basal-like and human epidermal growth factor receptor (HER)2/ER subtypes within the ER-negative subset, and the luminal A and B subtypes within ER-positive disease. The basal-like subtype is characterized by the low expression levels of the ER-related and the HER2-related group of genes, and therefore is often 'triple negative' on clinical assays for these proteins. This review discusses the molecular profiles of breast cancer with a focus on the clinical characteristics of, and treatment options for, the basal-like subtype.lld:pubmed
pubmed-article:17280502pubmed:languageenglld:pubmed
pubmed-article:17280502pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17280502pubmed:citationSubsetIMlld:pubmed
pubmed-article:17280502pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17280502pubmed:statusMEDLINElld:pubmed
pubmed-article:17280502pubmed:monthFeblld:pubmed
pubmed-article:17280502pubmed:issn1479-6694lld:pubmed
pubmed-article:17280502pubmed:authorpubmed-author:CareyLisa ALAlld:pubmed
pubmed-article:17280502pubmed:authorpubmed-author:FinneganTimot...lld:pubmed
pubmed-article:17280502pubmed:issnTypePrintlld:pubmed
pubmed-article:17280502pubmed:volume3lld:pubmed
pubmed-article:17280502pubmed:ownerNLMlld:pubmed
pubmed-article:17280502pubmed:authorsCompleteYlld:pubmed
pubmed-article:17280502pubmed:pagination55-63lld:pubmed
pubmed-article:17280502pubmed:meshHeadingpubmed-meshheading:17280502...lld:pubmed
pubmed-article:17280502pubmed:meshHeadingpubmed-meshheading:17280502...lld:pubmed
pubmed-article:17280502pubmed:meshHeadingpubmed-meshheading:17280502...lld:pubmed
pubmed-article:17280502pubmed:meshHeadingpubmed-meshheading:17280502...lld:pubmed
pubmed-article:17280502pubmed:meshHeadingpubmed-meshheading:17280502...lld:pubmed
pubmed-article:17280502pubmed:meshHeadingpubmed-meshheading:17280502...lld:pubmed
pubmed-article:17280502pubmed:year2007lld:pubmed
pubmed-article:17280502pubmed:articleTitleGene-expression analysis and the basal-like breast cancer subtype.lld:pubmed
pubmed-article:17280502pubmed:affiliationThe University of North Carolina, Division of Hematology/Oncology, CB#7305, 3009 Old Clinic Building, Chapel Hill, NC 27599, USA. tfinnega@unch.unc.edulld:pubmed
pubmed-article:17280502pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17280502pubmed:publicationTypeReviewlld:pubmed